NeurAxon gets $32M to advance pain therapies

Waltham, MA-based NeurAxon has pulled in $32 million in its second round of venture capital. Delphi Ventures and OrbiMed Advisors, two new investors, led the round. The money is earmarked for advancing the developer's pain therapies.

"NeurAxon's lead candidate, NXN-188, is designed to provide migraine relief through a dual mechanism of action, and we are encouraged by the early indications that this approach may provide significant improvements over current migraine treatments," said Deepa Pakianathan, Ph.D., general partner of Delphi Ventures.

- here's the release for more info

Suggested Articles

Shorla Pharma picked up $8.3 million to push its cancer programs through U.S. regulatory approval and gear up for its first drug launch in 2021.

Nodthera bagged $55 million to get its lead asset through phase 1 and into proof-of-concept studies, and a second program into the clinic.

Genor Biopharma banked $160 million from the likes of Hillhouse and Temasek Holdings to advance its clinical-stage autoimmune and cancer programs.